Hematopoietic Stem Cell Transplantation
Originally presented at HOPA's 13th Annual Conference, March 2017.
Update on Maintenance Chemotherapy Post Hematopoietic Stem Cell Transplantation
In-high risk patients, maintenance therapy following transplantation improves progression-free and overall survival. Discussion will include both the identification of high-risk patients who would benefit from maintenance therapy and the optimal timing for initiation of posttransplant treatment. This presentation will address the current role of maintenance therapy in patients with multiple myeloma, lymphoma, and leukemia and will target both beginning and advanced practitioners.
- Review the current recommendations for maintenance therapy in multiple myeloma, lymphoma, and leukemia after transplantation.
- Identify the ideal population and chemotherapy agent for maintenance therapy.
- Discuss the controversies and complications surrounding maintenance therapy.
Sarah Perreault, PharmD BCOP BCPS
Sarah Perreault is a clinical pharmacy specialist in bone marrow transplantation at Smilow Cancer Hospital at Yale–New Haven Hospital. She is also the PGY-2 oncology residency program director and adjunct assistant professor at St. Joseph’s School of Pharmacy. She earned her PharmD degree from the University of Connecticut. She completed her PGY-1 pharmacy residency at IU Health in Indianapolis, IN, and her PGY-2 residency in oncology at Mayo Clinic in Rochester, MN. She is actively involved in the expansion of pharmacy in outpatient bone marrow transplant and immunosuppressive infectious disease.
Patient Management & Therapeutics
Pharmacotherapeutic Considerations in T-Cell Replete Haploidentical Stem Cell Transplantation
This session will review the various approaches currently being used in T-cell replete haploidentical SCT. We will review the various conditioning regimens being used as well as supportive care given in T-cell replete SCT. Supportive care unique to this platform includes attention to infectious complications, organ toxicity, and dosing of conditioning chemotherapy. Also, the evidence supporting the use of this type of transplant in comparison to matched related and unrelated transplant as well as umbilical cord transplant will be explored. The BMT pharmacist should be aware of considerations in infectious disease prophylaxis, therapeutic drug monitoring, and supportive care.
- Review the preparative regimens that have been employed in T-cell replete haploidentical SCT.
- Determine the unique extrahematologic- and infectious-disease-related complications observed in T-cell replete haploidentical SCT.
- Review the efficacy and safety outcomes of haploidentical SCT compared to alternative donor transplants.
Karen Sweiss, PharmD BCOP
Karen Sweiss is a clinical assistant professor and clinical pharmacist in hematology and bone marrow transplantation (BMT) at the University of Illinois (UIC) College of Pharmacy. She has been practicing for 10 years and is interested particularly in research in acute myeloid leukemia, multiple myeloma, and haploidentical stem cell transplantation (SCT). She has presented at the American Society for Blood and Marrow Transplantation (ASBMT) on the role of SCT in sickle cell disease and recently gave a webinar on ASBMT updates from the organization’s 2016 conference in Hawaii. She has published, with her colleagues in BMT at UIC, several articles on BMT.
Patient Management & Therapeutics
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 29, 2020.
This activity has been approved for .1 CEU
This course is also included as part of the Best of AC2017 Bundle product.
Release Date: August 31, 2017
Expiration Date: March 29, 2020